Oxford BioTherapeutics Strikes Fourth License Deal with Boehringer Ingelheim for Novel Cancer Therapy

Oxford BioTherapeutics (OBT), a clinical stage oncology company, has announced that Boehringer Ingelheim has exercised its option on a fourth novel oncology target deriving from their existing discovery collaboration. This milestone triggers a payment to OBT, further validating their proprietary OGAP splice variant discovery platform. Leading efforts in immuno-oncology, OBT’s alliances include strategic relationships with industry leaders such as Boehringer Ingelheim, underpinning innovative cancer immunotherapy developments. Under the agreement, Boehringer will manage future development and commercialization of antibody products from the identified target, with OBT set to receive potential milestone payments and sales royalties. This collaboration is pivotal in pursuing groundbreaking cancer therapies, leveraging unique tumor antigens for a more precise immuno-oncological intervention.